99-27580. Draft Guidance for Industry on Developing Antimicrobial Drugs to Treat Catheter-Related Bloodstream Infections; Availability  

  • [Federal Register Volume 64, Number 203 (Thursday, October 21, 1999)]
    [Notices]
    [Page 56799]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-27580]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 99D-4328]
    
    
    Draft Guidance for Industry on Developing Antimicrobial Drugs to 
    Treat Catheter-Related Bloodstream Infections; Availability
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing the 
    availability of a draft guidance for industry entitled ``Catheter-
    Related Bloodstream Infections--Developing Antimicrobial Drugs for 
    Treatment.'' This draft guidance is one in a series of guidances being 
    developed to assist pharmaceutical manufacturers in developing 
    antimicrobial drug products.
    
    DATES: Written comments on the draft guidance may be submitted by 
    December 20, 1999. General comments on agency guidance documents are 
    welcome at any time.
    
    ADDRESSES: Copies of this draft guidance for industry are available on 
    the Internet at http://www.fda.gov/cder/guidance/index.htm. Submit 
    written requests for single copies of the draft guidance entitled 
    ``Catheter-Related Bloodstream Infections--Developing Antimicrobial 
    Drugs for Treatment'' to the Drug Information Branch (HFD-210), Center 
    for Drug Evaluation and Research, Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive 
    label to assist that office in processing your requests. Submit written 
    comments on the draft guidance to the Dockets Management Branch (HFA-
    305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
    Rockville, MD 20852.
    
    FOR FURTHER INFORMATION CONTACT: Renata Albrecht, Center for Drug 
    Evaluation and Research (HFD-590), Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857, 301-827-2336.
    
    SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a 
    draft guidance for industry entitled ``Catheter-Related Bloodstream 
    Infections--Developing Antimicrobial Drugs for Treatment.'' This is one 
    of a series of guidances under development to assist manufacturers in 
    planning the necessary clinical studies and designing and implementing 
    the clinical protocols for drug products to treat infections. This 
    draft guidance discusses catheter-related bloodstream infections, i.e., 
    bloodstream infections resulting from an infected vascular access 
    device or contaminated infusate. The issues raised in this draft 
    guidance will be discussed at a meeting of the Anti-Infective Drugs 
    Advisory Committee, scheduled for October 20, 1999 (64 FR 54335, 
    October 6, 1999).
        This level 1 draft guidance is being issued consistent with FDA's 
    good guidance practices (62 FR 8961, February 27, 1997). The draft 
    guidance represents the agency's current thinking on catheter-related 
    bloodstream infections. It does not create or confer any rights for or 
    on any person and does not operate to bind FDA or the public. An 
    alternative approach may be used if such approach satisfies the 
    requirements of the applicable statute, regulations, or both.
        Interested persons may submit written comments on the draft 
    guidance to the Dockets Management Branch (address above). Two copies 
    of any comments are to be submitted, except that individuals may submit 
    one copy. Comments are to be identified with the docket number found in 
    brackets in the heading of this document. The draft guidance and 
    received comments are available for public examination in the Dockets 
    Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
    
        Dated: October 15, 1999.
     Margaret M. Dotzel,
     Acting Associate Commissioner for Policy.
    [FR Doc. 99-27580 Filed 10-19-99; 11:59 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
10/21/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-27580
Dates:
Written comments on the draft guidance may be submitted by December 20, 1999. General comments on agency guidance documents are welcome at any time.
Pages:
56799-56799 (1 pages)
Docket Numbers:
Docket No. 99D-4328
PDF File:
99-27580.pdf